



## ASX Announcement

29<sup>th</sup> June 2020

# Presentation of Exenatide Phase II Data at Major Headache Congress

---

**Invex Therapeutics Ltd (Invex, ASX: IXC, or the Company)** today announced the results of its positive Phase II randomised, double blind, placebo controlled clinical trial comparing twice daily Exenatide against placebo in the treatment of Idiopathic Intracranial Hypertension (IIH) are to be presented by the study investigators during the scientific sessions at the 14th European Headache Federation (EHF) Congress on 29 June in Berlin, Germany (virtual Congress).

The presentation is entitled *“A randomised, placebo controlled, double blind trial of the effect of the GLP-1 receptor agonist Exenatide on intracranial pressure in Idiopathic Intracranial Hypertension (IIH: Pressure Trial).”*

Dr Jason Loveridge, Chairman of Invex said “The EHF has led the way in promoting headache science, making the best treatment available to everyone in need and improve the quality of medical care for people with headache. Additionally, the publication of consensus treatment guidelines for IIH in 2018 by the EHF has resulted in a standardised approach to the diagnosis and treatment of IIH patients across Europe. For Invex, the opportunity to undertake this level of scientific peer dissemination and review of our exciting positive Phase II clinical data, at such an important meeting, ahead of our planned submission for publication in a leading scientific journal in the second half of 2020 is welcomed.”

***This release dated 29<sup>th</sup> June has been authorised for lodgement to the ASX by the Board of Directors of Invex Therapeutics and lodged by Narelle Warren, Company Secretary.***

**ENDS**

---

### For more information, please contact:

#### Investors

Dr Thomas Duthy  
Nemean Group  
[tduthy@nemean.com.au](mailto:tduthy@nemean.com.au)  
+61 402 493 727

#### Media

Margie Livingston  
Ignite Communications  
[margie@ignitecommunications.com.au](mailto:margie@ignitecommunications.com.au)  
+61 438 661 131

## About Invex Therapeutics Ltd

---

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin™. [www.invextherapeutics.com](http://www.invextherapeutics.com).

## About Idiopathic Intracranial Hypertension (IIH)

---

IIH features severely raised intracranial pressure which causes disabling daily headaches and can compress the optic nerve, causing permanent vision loss in 25% of those affected. The usual age of onset is 20-30 years, and it is most common in women who are obese. IIH is a rapidly growing orphan indication: its incidence has increased by more than 350% in the last 10 years.

## About Exenatide

---

Exenatide is a small peptide and a synthetic version of the GLP-1 agonist exendin-4, which received approval in the US and Europe for the treatment of type 2 diabetes in 2005 and 2006 respectively. Professor Alexandra Sinclair's research showed that GLP-1 receptors are expressed in the choroid plexus in the brain and that Exenatide can bind to these receptors and reduce secretion of cerebrospinal fluid. Current Exenatide dosage forms are not optimised for IIH.